Shanghai INT Medical Instruments reports 24% profit increase

Shanghai INT Medical Instruments Co., Ltd. (HKEX: 1501) today announced its annual results for the year ended December 31, 2024, reporting a profit of RMB 190.05 million, a 24.03% increase from RMB 153.23 million in 2023. Revenue rose by 13.17% to RMB 851.95 million, driven by increased market demand and customer acquisition. Gross profit increased by 22.73% to RMB 537.66 million. Basic and diluted earnings per share both increased to RMB 1.10, a 19.57% rise. The company's board has opted not to declare a final dividend for the reporting period. As of December 31, 2024, the company’s cash and bank balance reached RMB 521.95 million and had total assets worth RMB 892.13 million. The company also repurchased 800,000 shares in April 2024 at HKD 26 per share. The company anticipates continued growth in 2025, focusing on expanding its product pipeline, and enhancing its manufacturing capabilities.